G. Wieland

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

Wendy S. Becker, G. Groenewegen, M. Eisenhut, 2003, British Journal of Cancer.

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).

H. Steininger, N. Lang, M. Gramatzki, 1995, Journal of hematotherapy.